WHO/BS/2022.2428: Collaborative Study to Evaluate Candidate 1st WHO International Standardsfor Antibodies to Human Papillomavirus Types 6,11, 31, 33, 45, 52 and 58

Overview

This report describes the development and worldwide collaborative study evaluation of the candidate 1st WHO International Standards (IS) for antibodies to human papillomavirus (HPV) Type 6, HPV Type 11, HPV Type 31, HPV Type 33, HPV Type 45, HPV Type 52, and HPV Type 58. The availability of these International Standards will facilitate the standardization of HPV serological methods, which will help determine antibody levels associated with efficacy for
each of the HPV types contained in HPV vaccines. Furthermore, the harmonization across laboratories using the International Standards will allow for the efficient comparison of serological data from serosurveillance studies and vaccine efficacy studies to advance our understanding of serological minimal levels of protection from viral infection.